Teva Pharmaceutical Industries Investor Presentation — August 2018

Document content

Teva Pharmaceutical Industries Ltd.

August 2, 2018 Cautionary Note Regarding Forward-Looking Statements 2

This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to

substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward -looking statements.

Important factors that could cause or contribute to such differences include risks relating to:

• our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic product s; competition for our specialty products, especially COPAXONE®, our leading medicine,

which faces competition from existing and potential additional generic versions and orally -administered alternatives; competitio n from companies with greater resources and capabilities; efforts of pharmaceutical companies

to limit the use of generics including through legislation and regulations; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic

opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our products, both from competing products and increased regulation; delays in launches of new

products and our ability to achieve expected results from investments in our product pipeline; our ability to take advantage of high -value opportunities; the difficulty and expense of obtaining licenses to proprietary

technologies; and the effectiveness of our patents and other measures to protect our intellectual property rights;

• our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings;

and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;

• our business and operations in general, including: failure to effectively execute our restructuring plan announced in Decembe r 2017; uncertainties related to, and failure to achieve, the potential benefits and success

of our new senior management team and organizational structure; harm to our pipeline of future products due to the ongoing re view of our R&D programs; our ability to develop and commercialize additional

pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. government of our F CPA investigation; compliance with sanctions and other trade control laws; manufacturing or